DiaMedica Therapeutics (DMAC) Stock Forecast, Price Target & Predictions
DMAC Stock Forecast
DiaMedica Therapeutics stock forecast is as follows: an average price target of $8.33 (represents a 107.21% upside from DMAC’s last price of $4.02) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
DMAC Price Target
DMAC Analyst Ratings
Buy
DiaMedica Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 07, 2024 | Bill Chappell | Truist Financial | $10.00 | $4.42 | 126.46% | 148.76% |
Oct 07, 2024 | Matthew Caufield | H.C. Wainwright | $7.00 | $4.36 | 60.55% | 74.13% |
Mar 21, 2024 | Alex Nowak | Craig-Hallum | $8.00 | $2.69 | 197.40% | 99.00% |
10
DiaMedica Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 2 | 3 |
Avg Price Target | - | $8.50 | $8.33 |
Last Closing Price | $4.02 | $4.02 | $4.02 |
Upside/Downside | -100.00% | 111.44% | 107.21% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 07, 2024 | H.C. Wainwright | - | Buy | Initialise |
Jun 22, 2023 | Oppenheimer | - | Outperform | Upgrade |
Jun 22, 2023 | Oppenheimer | - | Hold | Upgrade |
Jul 07, 2022 | Lake Street | Buy | Buy | Hold |
Jul 07, 2022 | Craig-Hallum | Buy | Buy | Hold |
10
DiaMedica Therapeutics Financial Forecast
DiaMedica Therapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $13.50M | $13.50M | $13.50M | $13.50M | - | - | - | - | - | - | - |
High Forecast | $13.50M | $13.50M | $13.50M | $13.50M | - | - | - | - | - | - | - |
Low Forecast | $13.50M | $13.50M | $13.50M | $13.50M | - | - | - | - | - | - | - |
# Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
DiaMedica Therapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
DiaMedica Therapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-8.12M | $-8.12M | $-8.12M | $-8.12M | $-9.83M | $-10.26M | $-8.98M | $-8.55M | $-7.37M | $-6.63M | $-5.96M |
High Forecast | $-8.12M | $-8.12M | $-8.12M | $-8.12M | $-9.83M | $-10.26M | $-8.98M | $-8.55M | $-6.91M | $-6.63M | $-5.96M |
Low Forecast | $-8.12M | $-8.12M | $-8.12M | $-8.12M | $-9.83M | $-10.26M | $-8.98M | $-8.55M | $-7.37M | $-6.63M | $-5.96M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
DiaMedica Therapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
DiaMedica Therapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.19 | $-0.19 | $-0.19 | $-0.19 | $-0.23 | $-0.24 | $-0.21 | $-0.20 | $-0.17 | $-0.15 | $-0.16 |
High Forecast | $-0.19 | $-0.19 | $-0.19 | $-0.19 | $-0.23 | $-0.24 | $-0.21 | $-0.20 | $-0.16 | $-0.15 | $-0.16 |
Low Forecast | $-0.19 | $-0.19 | $-0.19 | $-0.19 | $-0.23 | $-0.24 | $-0.21 | $-0.20 | $-0.17 | $-0.15 | $-0.16 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
DiaMedica Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
MIST | Milestone Pharmaceuticals | $1.86 | $10.00 | 437.63% | Buy |
IKT | Inhibikase Therapeutics | $1.98 | $6.50 | 228.28% | Buy |
DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
IOVA | Iovance Biotherapeutics | $8.14 | $21.00 | 157.99% | Buy |
TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
DMAC | DiaMedica Therapeutics | $4.02 | $8.33 | 107.21% | Buy |
MCRB | Seres Therapeutics | $0.81 | $1.25 | 54.32% | Buy |
CNTA | Centessa Pharmaceuticals | $16.74 | $23.25 | 38.89% | Buy |
HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |